Geometrical Construction of Heterogeneous Loop Amplitudes in 2D Gravity

We study a disk amplitude which has a complicated heterogeneous matter configuration on the boundary in a system of the (3,4) conformal matter coupled to two-dimensional gravity. It is analyzed using the two-matrix chain model in the large N limit. We show that the disk amplitude calculated by Schwinger-Dyson equations can completely be reproduced through purely geometrical consideration. From this result, we speculate that all heterogeneous loop amplitudes can be derived from the geometrical consideration and the consistency among relevant amplitudes.Comment: 13 pages, 11 figure

Interaction of boundaries with heterogeneous matter states in matrix models

We study disk amplitudes whose boundary conditions on matter configurations are not restricted to homogeneous ones. They are examined in the two-matrix model as well as in the three-matrix model for the case of the tricritical Ising model. Comparing these amplitudes, we demonstrate relations between degrees of freedom of matter states in the two models. We also show that they have a simple geometrical interpretation in terms of interactions of the boundaries. It plays an important role that two parts of a boundary with different matter states stick each other. We also find two closed sets of Schwinger-Dyson equations which determine disk amplitudes in the three-matrix model.Comment: 20 pages, LaTex, 2 eps figures, comments added, introduction replaced, version to appear in Nuclear Physics

ALK7 is a novel marker for adipocyte differentiation

Transforming growth factor-β (TGF-β) family members regulate a variety of cellular functions and play important roles in cell differentiation. Activin receptor-like kinase 7 (ALK7), a receptor for TGF-β family members, was initially cloned from rats as an orphan receptor and has been recently shown to be a type I receptor for nodal, activin B and activin AB. ALK7 is expressed not only in neurons, but also in insulin-producing islet β cells and white and brown adipose tissues however, the specific functions of ALK7 in these tissues are not known. In order to test whether ALK7 is involved in adipocyte differentiation, we analyzed its expression during adipocyte differentiation. ALK7 expression was detected in the late phase of adipocyte differentiation by reverse transcriptase-polymerase chain reaction (RT-PCR), Western blotting and immunofluorescence staining in 3T3-L1 cells. We also detected the expression of ALK7 by RT-PCR in stromal vascular fraction (SVF) cells. These results indicated that ALK7 is a novel marker specifically expressed during the late phase of adipocyte differentiation. Furthermore, our results suggest the possible involvement of nodal or activin B in adipocyte differentiation

Ambient dose rate in Mikurashima Island after the Fukushima Daiichi Nuclear Power Plant accident

No detailed ambient dose rate has been reported, either before or after the Fukushima Daiichi Nuclear Power Plant (F1-NPP) accident, for Mikurashima Island, one of the islands within the authority of the Tokyo Metropolitan Government. Thus, the ambient dose rate on Mikurashima Island was observed 4.5 years after the F1-NPP accident. A car-borne survey and a foot patrol survey of the ambient dose rates were conducted over the entire island using a 3-in × 3-in NaI(Tl) scintillation spectrometer. The average ambient dose rate was 27 nGy h^-1 (12 – 45 nGy h^-1) and a higher dose distribution was observed for the northern and eastern areas of Mikurashima Island. However, the impact from the F1-NPP accident (i.e., the presence of artificial radionuclides) was mainly observed for the mountain area of the island (4 – 9 nGy h^-1; located about the center to south-southeast direction). Based on the measured ambient dose rate, the estimated annual effective dose after the accident was 0.09 mSv y^-1

Natural Variation of Ambient Dose Rate in Air of Izu-Oshima Island After the Fukushima Daiichi Nuclear Power Plant Accident

The ambient dose rate in air and radioactivity concentration in soil samples collected on Izu-Oshima Island were observed in 2012, 2013 and 2014, i.e., one, two and three years after the severe accident at the Fukushima Daiichi Nuclear Power Plant. A car-borne survey for the ambient dose rate in air was carried out for the entire island. Soil samples were collected for the radioactivity concentration measurements from 22 points. The ambient dose rates in air were 36 nGy h⁻¹ in 2012, 34 nGy h⁻¹ in 2013 and 29 nGy h⁻¹ in 2014, respectively. The corresponding radioactivity concentrations in those years for ¹³⁴Cs were 53 Bq kg⁻¹, 39 Bq kg⁻¹ and 29 Bq kg⁻¹ and for ¹³⁷Cs, 87 Bq kg⁻¹, 73 Bq kg⁻¹ and 75 Bq kg⁻¹. All the values have decreased every year

Activin E Controls Energy Homeostasis in Both Brown and White Adipose Tissues as a Hepatokine

Brown adipocyte activation or beige adipocyte emergence in white adipose tissue (WAT) increases energy expenditure, leading to a reduction in body fat mass and improved glucose metabolism. We found that activin E functions as a hepatokine that enhances thermogenesis in response to cold exposure through beige adipocyte emergence in inguinal WAT (ingWAT). Hepatic activin E overexpression activated thermogenesis through Ucp1 upregulation in ingWAT and other adipose tissues including interscapular brown adipose tissue and mesenteric WAT. Hepatic activin E-transgenic mice exhibited improved insulin sensitivity. Inhibin βE gene silencing inhibited cold-induced Ucp1 induction in ingWAT. Furthermore, in vitro experiments suggested that activin E directly stimulated expression of Ucp1 and Fgf21, which was mediated by transforming growth factor-β or activin type I receptors. We uncovered a function of activin E to stimulate energy expenditure through brown and beige adipocyte activation, suggesting a possible preventive or therapeutic target for obesity

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation